

2020 NMH MICU *P. aeruginosa* Combination Antibigram

Organisms	Isolates	Aztreonam + Ciprofloxacin	Aztreonam + Tobramycin	Cefepime + Ciprofloxacin	Cefepime + Tobramycin	Meropenem + Amikacin	Meropenem + Ciprofloxacin	Meropenem + Tobramycin	Piperacillin-tazobactam + Ciprofloxacin	Piperacillin-tazobactam + Tobramycin
<i>Pseudomonas aeruginosa</i>	77	87	93	85	94	97	88	93	87	93

30 isolate threshold

Not all isolates tested against every antibiotic listed

Antibiogram Guidance:

- ❖ The numbers displayed above represent the percentage of organisms susceptible to the specified antibiotic.
- ❖ Antibiogram data helps guide clinicians to choose appropriate empiric antibiotics for many infectious syndromes.
- ❖ Clinical practice guidelines generally recommend selecting antibiotics with > 80% susceptibility for the most likely pathogens.
- ❖ For empiric prescribing guidance please visit asp.nm.org/northwestern-memorial.html

Note: combination therapy for *Pseudomonas aeruginosa* is not routinely recommended for definitive therapy as controlled trials have not established superior clinical outcomes over monotherapy with an *in vitro* active antibiotic